R
22.68
0.27 (1.20%)
| Previous Close | 22.41 |
| Open | 22.20 |
| Volume | 7,566,553 |
| Avg. Volume (3M) | 8,282,271 |
| Market Cap | 15,773,749,248 |
| Price / Sales | 748.21 |
| Price / Book | 3.47 |
| 52 Weeks Range | |
| Earnings Date | 9 Feb 2026 |
| Operating Margin (TTM) | -4,823.84% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -16.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 33.47 |
| Operating Cash Flow (TTM) | -839.45 M |
| Levered Free Cash Flow (TTM) | -375.20 M |
| Return on Assets (TTM) | -10.73% |
| Return on Equity (TTM) | -12.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Roivant Sciences Ltd. | Bullish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | 4.0 |
| Insider Activity | -5.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | -0.10 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 30.31% |
| % Held by Institutions | 83.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Qvt Financial Lp | 30 Sep 2025 | 29,381,635 |
| Patient Square Capital Lp | 30 Sep 2025 | 12,480,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (Goldman Sachs, 45.50%) | Buy |
| Median | 29.00 (27.87%) | |
| Low | 26.00 (HC Wainwright & Co., 14.64%) | Buy |
| 26.00 (Citigroup, 14.64%) | Buy | |
| Average | 29.25 (28.97%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 21.70 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 15 Dec 2025 | 33.00 (45.50%) | Buy | 21.90 |
| Leerink Partners | 15 Dec 2025 | 32.00 (41.09%) | Buy | 21.90 |
| HC Wainwright & Co. | 12 Dec 2025 | 26.00 (14.64%) | Buy | 22.10 |
| Citigroup | 11 Nov 2025 | 26.00 (14.64%) | Buy | 20.90 |
| 29 Oct 2025 | 25.00 (10.23%) | Buy | 18.76 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GLINE MATTHEW | - | 21.90 | -3,870,659 | -84,767,432 |
| GOLD DANIEL ALLEN | - | 22.82 | -1,694,614 | -38,687,885 |
| MANCHESTER KEITH S | - | 22.82 | -1,694,614 | -38,687,885 |
| QVT FINANCIAL LP | - | 22.82 | -1,694,614 | -38,687,885 |
| RAMASWAMY VIVEK | - | 21.78 | -7,374,869 | -161,397,148 |
| Aggregate Net Quantity | -16,329,370 | |||
| Aggregate Net Value ($) | -362,228,237 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 22.24 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| QVT FINANCIAL LP | 17 Dec 2025 | Sell (-) | 777,332 | 22.70 | 17,645,436 | |
| MANCHESTER KEITH S | Director | 17 Dec 2025 | Sell (-) | 777,332 | 22.70 | 17,645,436 |
| GOLD DANIEL ALLEN | Director | 17 Dec 2025 | Sell (-) | 777,332 | 22.70 | 17,645,436 |
| QVT FINANCIAL LP | 16 Dec 2025 | Sell (-) | 917,282 | 22.94 | 21,042,449 | |
| MANCHESTER KEITH S | Director | 16 Dec 2025 | Sell (-) | 917,282 | 22.94 | 21,042,449 |
| GOLD DANIEL ALLEN | Director | 16 Dec 2025 | Sell (-) | 917,282 | 22.94 | 21,042,449 |
| RAMASWAMY VIVEK | 15 Dec 2025 | Sell (-) | 353,745 | 21.90 | 7,747,016 | |
| RAMASWAMY VIVEK | 15 Dec 2025 | Disposed (-) | 478,708 | 21.90 | 10,483,705 | |
| RAMASWAMY VIVEK | 15 Dec 2025 | Option execute | 832,453 | - | - | |
| GLINE MATTHEW | Officer | 15 Dec 2025 | Sell (-) | 1,740,000 | 21.90 | 38,106,000 |
| GLINE MATTHEW | Officer | 15 Dec 2025 | Disposed (-) | 2,130,659 | 21.90 | 46,661,432 |
| GLINE MATTHEW | Officer | 15 Dec 2025 | Option execute | 3,870,659 | - | - |
| RAMASWAMY VIVEK | 12 Dec 2025 | Sell (-) | 1,975,858 | 22.10 | 43,666,462 | |
| RAMASWAMY VIVEK | 12 Dec 2025 | Disposed (-) | 2,696,866 | 22.10 | 59,600,739 | |
| RAMASWAMY VIVEK | 12 Dec 2025 | Option execute | 4,672,724 | - | - | |
| RAMASWAMY VIVEK | 11 Dec 2025 | Sell (-) | 774,142 | 21.34 | 16,520,190 | |
| RAMASWAMY VIVEK | 11 Dec 2025 | Disposed (-) | 1,095,550 | 21.34 | 23,379,037 | |
| RAMASWAMY VIVEK | 11 Dec 2025 | Option execute | 1,869,691 | - | - | |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 11 Dec 2025 | Announcement | Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day |
| 10 Nov 2025 | Announcement | Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update |
| 27 Oct 2025 | Announcement | Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |